Intravenous Cangrelor as a Peri-Procedural Bridge With Applied Uses in Ischemic Events
Cangrelor is a relatively new antiplatelet drug that has been approved for use as an adjunct therapy to percutaneous coronary intervention (PCI) to decrease peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis. Cangrelor is an adenosine triphosphate analogue with a pharmacokinetic mechanism based on a reversible, dose-dependent inhibition adenosine diphosphate (ADP)-induced platelet aggregation. This drug has lately been in the spotlight as a possible bridge therapy for anti-platelet medication prior to cardiac and non-cardiac surgeries. Platelet function is usually restored within sixty minutes of cessation of therapy, thereby decreasing the risk of bleeding while providing adequate pre-procedural coverage to reduce ischemic events. This manuscript reviews the literature on cangrelor and summarizes its role as a peri-procedural bridge.
Bhattad, Venugopal B.; Gaddam, Sathvika; Lassiter, Margaret A.; Jagadish, Pooja S.; Ardeshna, Devarshi; Cave, Brandon; and Khouzam, Rami N., "Intravenous Cangrelor as a Peri-Procedural Bridge With Applied Uses in Ischemic Events" (2019). ETSU Faculty Works. 152.